Biomarker ID | 1187 |
PMID | 23918943 |
Year | 2013 |
Biomarker | Methylation Status of C1orf114 (as continous variable) |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Lower Methylation in Patients with Longer Survival |
Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: Univariate: [4.74 (95% CI: 3.00 to 7.48)]; Multivariate: [3.10 (95% CI: 1.89 to 5.09)]Cohort 2: Univariate: [5.37 (95% CI: 1.99 to 14.5)]; Multivariate: [0.74 (95% CI: 1.17 to 9.12)] |
Effect on Pathways | Pathways include: CACNA1D knockdown 96h PC3, CHEK2 knockdown 96h A549, NR2C1 knockdown 96h HCC515 , CAMK2D knockdown 96h PC3, SNRK knockdown 96h PC3 |
Experiment | Biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | 0.892 |
Accuracy | NA |
Level Of Significance | P < 0.001 |
Method Used | quantitative methylation specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | C1orf114 |